TickerFacts.

DBV Technologies S.A. (DBVT): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$2.99M
Year ended 2025-12-31
$3.57M2023-12-31: $3.57M2024-12-31: $2.72M2025-12-31: $2.99M$2.99M
2023-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$2.99M+9.8%2026-03-26, From 2025-01-01
2024-12-31$2.72M-23.7%2026-03-26, From 2024-01-01
2023-12-31$3.57Mn/a2025-04-11, From 2023-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
DBV Technologies S.A. (DBVT)2025-12-31$2.99M+9.8%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$73.0K-1.4%
Fate Therapeutics Inc (FATE)2025-12-31$12.90M-32.0%
Prime Medicine, Inc. (PRME)2025-12-31$7.32M+19.5%
CG Oncology, Inc. (CGON)2025-12-31$1.45Mn/m
CRISPR Therapeutics AG (CRSP)2025-12-31$19.48M+1.1%
Surrozen, Inc. (SRZN)2025-12-31$537.0K-62.8%
Curis Inc (CRIS)2025-12-31$169.0K-16.7%
Alpha Cognition Inc. (ACOG)2025-12-31$58.6K-27.9%

Compare DBVT, ZEOX, FATE, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗